Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
37967
CAS Number:
152459-95-5
Imatinib
Purity:
≥ 98% (HPLC)
Documents
$56.99 /100MG
Pack Size Availability Price
Request Bulk Quote
Product Information

Imatinib is a potent tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). This compound works by selectively inhibiting the BCR-ABL fusion protein, which is responsible for the uncontrolled proliferation of cancer cells in CML. Its unique mechanism of action allows for targeted therapy, minimizing damage to healthy cells and reducing side effects compared to traditional chemotherapy.

In addition to its primary applications in oncology, Imatinib has shown promise in treating other conditions such as systemic mastocytosis and dermatofibrosarcoma protuberans. Researchers and healthcare professionals appreciate its efficacy and safety profile, making it a cornerstone in cancer treatment protocols. With ongoing studies exploring its potential in various malignancies, Imatinib continues to be a critical compound in advancing cancer therapy and improving patient outcomes.

CAS Number
152459-95-5
Purity
≥ 98% (HPLC)
Molecular Formula
C29H31N7O
Molecular Weight
493.62
MDL Number
MFCD05662257
PubChem ID
5291
Melting Point
207 - 211 °C
Appearance
White to light yellow to light orange powder to crystal
Conditions
Store at < 0 °C
General Information
CAS Number
152459-95-5
Purity
≥ 98% (HPLC)
Molecular Formula
C29H31N7O
Molecular Weight
493.62
MDL Number
MFCD05662257
PubChem ID
5291
Melting Point
207 - 211 °C
Appearance
White to light yellow to light orange powder to crystal
Conditions
Store at < 0 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
No
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Imatinib is widely utilized in research focused on

  • Cancer Treatment: Primarily known for its effectiveness in treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), Imatinib targets specific tyrosine kinases, offering a targeted approach that minimizes damage to healthy cells compared to traditional chemotherapy.
  • Research on Drug Resistance: Researchers use Imatinib to study mechanisms of drug resistance in cancer cells, providing insights into how tumors adapt and develop resistance, which can lead to the development of new therapeutic strategies.
  • Combination Therapies: Imatinib is often tested in combination with other drugs to enhance treatment efficacy. This application is crucial in oncology, as it may improve outcomes for patients who do not respond to single-agent therapies.
  • Pharmacogenomics: The drug is used in studies examining genetic variations that affect patient responses to treatment, helping to personalize cancer therapy based on individual genetic profiles.
  • Development of New Inhibitors: Researchers leverage the knowledge gained from Imatinib's mechanism of action to design and develop new inhibitors that target similar pathways, potentially leading to more effective treatments for various cancers.

Citations